Abstract Background and Aim Colorectal cancer (CRC) is the second leading cause of
cancer death worldwide. To improve outcomes for these patients, we need to develop new …

Background The inability to predict treatment response of colorectal cancer patients results
in unnecessary toxicity, decreased efficacy and survival. Response testing on patient …

BACKGROUND: Recent studies have shown patient-derived tumor organoids can predict
the drug response of patients with cancer. However, the prognostic value of patient-derived …

Organoid technology has been remarkably improved over the last decade. Various
organoids have been derived from different types of tissues and recapitulate their organ …

Background Recently, cancer organoid-based drug sensitivity tests have been studied to
predict patient responses to anticancer drugs. The area under curve (AUC) or IC50 value of …

Background Patient-derived organoids and xenografts (PDXs) have emerged as powerful
models in functional diagnostics with high predictive power for anticancer drug response …

Simple Summary The biopharmaceutical industry increasingly focuses on the development
of new anticancer drugs for effective cancer therapy. Despite these efforts, the success rate …

Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient
response to chemotherapy. However, the cutoff value of the half-maximal inhibition …

Tumor development and progression require chemical and mechanical cues derived from
cellular and non-cellular components in the tumor microenvironment, including the …

Unlike cancer cell lines, tumors and primary cultured cells exhibit phenotypic heterogeneity.
Although methods for establishing organoids within three-dimensional (3D) gels are well …